Engineered exosomes - Capricor Therapeutics
Alternative Names: Cardiosphere-Derived Exosomes; CDC-EVsLatest Information Update: 17 Nov 2021
At a glance
- Originator Capricor Therapeutics
- Developer Capricor Therapeutics; US Army Institute of Surgical Research
- Class Exosome therapies; MicroRNAs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haemorrhagic shock; Traumatic brain haemorrhage
Most Recent Events
- 04 Aug 2021 Preclinical trials in Haemorrhagic shock in USA (Parenteral)
- 04 Aug 2021 Preclinical trials in Traumatic brain haemorrhage in USA (Parenteral)
- 09 Mar 2021 Capricor Therapeutics in-licenses cardiosphere-derived cells (CDC)-exosome technology IP rights from Cedars-Sinai Medical Center (Capricor Therapeutics pipeline, March 2021)